Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced that its lead oncology compound, ANG1005, a novel paclitaxel-peptide drug conjugate in development for breast cancer patients with brain metastasis and patients with primary brain cancer, and ANG4043, a peptide-antibody conjugate of anti-HER2 in development for neuro-oncology indications, have been selected for presentation at the 2013 San Antonio Breast Cancer Symposium being held December 10-14, 2013 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
Help employers find you! Check out all the jobs and post your resume.
